Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
WilmerHale has played a leading role in shaping the rules that govern the US financial services industry.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Beam Therapeutics Inc. (Nasdaq: BEAM) announced that it has entered into a strategic financing agreement with Sixth Street Lending Partners as agent, which provides for a senior secured term loan facility of up to $500 million, consisting of an initial draw of $100 million and potential additional draws of $400 million upon meeting certain requirements. The closing of the term loan facility occurred on February 24, 2026. Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing. 

WilmerHale advised Beam Therapeutics on the transaction. 

The WilmerHale team consisted of George Shuster, Nathan Moore, Alex Dean, Michael Katz, Jane Cha and Rebecca Beames, with assistance from Cynthia Mazareas, Steven Barrett, Meghan Walsh, Stephanie Leopold, Tim Silva, Annaka Merrick and Lorri Strizich.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel